{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-107753","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.257633+00:00","generated_at":"2026-05-16T23:32:39.031646+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Protagonist Q3 net loss $39.3M (-$0.62); cash $678.8M; icotrokinra filed, rusfertide NDA expected Q4","bullets":["Net loss of $39.3M ($0.62 diluted EPS loss) vs $33.2M loss in Q3 2024.","Cash $678.8M, up from $559.2M at year-end 2024; provides runway through at least end 2028.","Icotrokinra NDA submitted to FDA (July) and EMA (September) for moderate-to-severe plaque psoriasis.","Rusfertide granted FDA Breakthrough Therapy designation; Phase 3 VERIFY 52-week data at ASH Dec 2025; NDA filing expected Q4 2025.","First patient dosed in Phase 1 for oral IL-17 antagonist PN-881."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-107753","json":"https://secwatch.observer/filing/0001104659-25-107753.json","markdown":"https://secwatch.observer/filing/0001104659-25-107753.md","text":"https://secwatch.observer/filing/0001104659-25-107753.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925107753/0001104659-25-107753-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925107753/tm2530353d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:32:39.031646+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}